NASDAQ:ARGX - argenx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $247.44
  • Forecasted Upside: -1.19 %
  • Number of Analysts: 20
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 16 Buy Ratings
  • 0 Strong Buy Ratings
$250.42
▼ -1.82 (-0.72%)
1 month | 3 months | 12 months
Get New argenx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$247.44
▼ -1.19% Downside Potential
This price target is based on 20 analysts offering 12 month price targets for argenx in the last 3 months. The average price target is $247.44, with a high forecast of $300.00 and a low forecast of $160.00. The average price target represents a -1.19% upside from the last price of $250.42.
Buy
The current consensus among 20 contributing investment analysts is to buy stock in argenx.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/31/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 15 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/25/2020
  • 0 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/25/2020

Latest Recommendations

  • 0 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2020BarclaysReiterated RatingEqual WeightLow
i
10/23/2020HC WainwrightLower Price TargetNeutral$272.00 ➝ $265.00Medium
i
Rating by D. Tsao at HC Wainwright
10/13/2020BarclaysReiterated RatingEqual WeightMedium
i
10/6/2020Bank of AmericaBoost Price TargetBuy$265.00 ➝ $298.00Low
i
10/6/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$265.00 ➝ $275.00Low
i
10/5/2020JMP SecuritiesBoost Price TargetOutperform$245.00 ➝ $271.00High
i
9/30/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$258.00 ➝ $300.00Low
i
8/24/2020Raymond JamesInitiated CoverageOutperform$257.00Medium
i
8/10/2020Morgan StanleyBoost Price TargetOverweight$258.00 ➝ $281.00Medium
i
7/31/2020Kepler Capital MarketsDowngradeBuy ➝ HoldLow
i
7/30/2020Stifel NicolausReiterated RatingBuy$253.00Medium
i
Rating by Derek Archila at Stifel Nicolaus
7/29/2020HC WainwrightInitiated CoverageNeutral$272.00High
i
Rating by D. Tsao at HC Wainwright
6/17/2020CowenReiterated RatingBuyLow
i
5/29/2020JPMorgan Chase & Co.Boost Price TargetOverweight$179.00 ➝ $246.00Medium
i
5/27/2020Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $258.00Low
i
5/27/2020GuggenheimReiterated RatingBuy$201.00 ➝ $225.00Medium
i
5/27/2020Robert W. BairdBoost Price TargetPositive ➝ Outperform$170.00 ➝ $235.00Medium
i
5/27/2020SunTrust BanksBoost Price TargetBuy$192.00 ➝ $240.00Medium
i
5/26/2020JMP SecuritiesBoost Price TargetOutperform$170.00 ➝ $237.00High
i
Rating by Jason Butler at JMP Securities
5/26/2020Piper SandlerBoost Price Target$198.00 ➝ $258.00High
i
5/26/2020Stifel NicolausBoost Price TargetPositive ➝ Buy$163.00 ➝ $253.00High
i
Rating by Derek Archila at Stifel Nicolaus
5/21/2020Credit Suisse GroupBoost Price TargetNeutral$150.00 ➝ $160.00Medium
i
5/17/2020NomuraReiterated RatingBuy$255.00High
i
5/14/2020Stifel NicolausReiterated RatingBuy$163.00High
i
Rating by Derek Archila at Stifel Nicolaus
3/4/2020Nomura SecuritiesReiterated RatingBuy$255.00High
i
2/24/2020GuggenheimBoost Price TargetBuy$164.00 ➝ $201.00Low
i
2/10/2020Bank of AmericaInitiated CoverageBuy$181.00Low
i
1/17/2020WedbushReiterated RatingOutperform$184.00 ➝ $184.00Low
i
1/17/2020Morgan StanleyBoost Price TargetOverweight$170.00 ➝ $180.00Medium
i
1/9/2020WedbushBoost Price TargetPositive ➝ Outperform$179.00 ➝ $184.00Medium
i
1/9/2020JMP SecuritiesReiterated RatingOutperform$164.00 ➝ $170.00Medium
i
1/9/2020Stifel NicolausReiterated RatingBuy ➝ AverageHigh
i
1/6/2020Piper Jaffray CompaniesBoost Price TargetOverweight$177.00 ➝ $194.00N/A
i
12/16/2019SunTrust BanksBoost Price TargetBuy$160.00 ➝ $192.00Medium
i
12/8/2019Stifel NicolausBoost Price TargetBuy$154.00 ➝ $170.00High
i
11/18/2019SunTrust BanksBoost Price TargetBuy$150.00 ➝ $160.00Low
i
11/8/2019Piper Jaffray CompaniesReiterated RatingOverweightLow
i
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$137.00 ➝ $137.00Low
i
10/31/2019William BlairUpgradeMarket Perform ➝ OutperformLow
i
10/22/2019JPMorgan Chase & Co.Initiated CoverageOverweight$167.00Low
i
9/27/2019Wells Fargo & CompanyInitiated CoverageMarket Perform$125.00Medium
i
9/13/2019CowenInitiated CoverageBuyMedium
i
Rating by Yaron Werber at Cowen Inc
8/6/2019Morgan StanleyBoost Price TargetOverweight$143.00 ➝ $173.00Medium
i
8/2/2019WedbushBoost Price TargetOutperform$144.00 ➝ $170.00Low
i
8/1/2019Stifel NicolausReiterated RatingBuy$154.00Low
i
Rating by Derek Archila at Stifel Nicolaus
6/27/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$170.00High
i
5/23/2019Piper Jaffray CompaniesBoost Price TargetOverweight$161.00 ➝ $182.00High
i
5/22/2019Stifel NicolausSet Price TargetBuy$154.00High
i
Rating by Derek Archila at Stifel Nicolaus
3/1/2019WedbushBoost Price TargetOutperform ➝ Outperform$131.00 ➝ $144.00Medium
i
2/22/2019GuggenheimInitiated CoverageBuy$157.00High
i
2/4/2019Stifel NicolausReiterated RatingBuyLow
i
Rating by Derek Archila at Stifel Nicolaus
1/18/2019SunTrust BanksReiterated RatingBuy ➝ BuyLow
i
1/4/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$140.00Low
i
12/17/2018Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$154.00Low
i
Rating by Graig Suvannavejh at Goldman Sachs Group Inc
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
i
12/9/2018CowenReiterated RatingBuyLow
i
12/4/2018Piper Jaffray CompaniesBoost Price TargetOverweight$154.00 ➝ $161.00Low
i
12/4/2018WedbushBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $131.00Medium
i
11/5/2018WedbushReiterated RatingOutperform ➝ Outperform$130.00 ➝ $125.00Medium
i
11/1/2018Stifel NicolausReiterated RatingBuyHigh
i
Rating by Derek Archila at Stifel Nicolaus
10/25/2018Stifel NicolausSet Price TargetBuy$139.00Low
i
Rating by Derek Archila at Stifel Nicolaus
10/16/2018Stifel NicolausSet Price TargetBuy$139.00High
i
Rating by Derek Archila at Stifel Nicolaus
10/15/2018Evercore ISIInitiated CoverageOutperform$110.00Medium
i
10/10/2018Stifel NicolausReiterated RatingBuy$139.00High
i
9/18/2018SunTrust BanksBoost Price TargetBuy ➝ In-Line$132.00High
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
9/18/2018WedbushBoost Price TargetOutperform ➝ Positive$114.00 ➝ $121.00High
i
9/17/2018JMP SecuritiesBoost Price TargetOutperform$150.00High
i
9/17/2018Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$154.00High
i
9/13/2018Stifel NicolausInitiated CoverageBuy$139.00High
i
6/29/2018Nomura SecuritiesInitiated CoverageBuy$161.00High
i
6/25/2018WedbushBoost Price TargetOutperform ➝ Outperform$93.00 ➝ $114.00High
i
6/18/2018JMP SecuritiesBoost Price TargetPositive$93.00 ➝ $130.00Low
i
6/14/2018CowenReiterated RatingBuyLow
i
6/7/2018Piper Jaffray CompaniesReiterated RatingOverweight$130.00Medium
i
6/6/2018CowenReiterated RatingBuyHigh
i
5/10/2018WedbushReiterated RatingOutperform$93.00 ➝ $92.00Low
i
4/26/2018WedbushBoost Price TargetOutperform ➝ Outperform$88.00 ➝ $92.00Low
i
4/8/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$125.00High
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
1/29/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$74.00 ➝ $87.00High
i
12/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$100.00Low
i
11/16/2017WedbushReiterated RatingOutperform$26.00 ➝ $41.00N/A
i
Rating by D. Nierengarten at Wedbush
8/24/2017CowenReiterated RatingBuyLow
i
Rating by Boris Peaker at Cowen Inc
6/12/2017WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
6/12/2017JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$33.00High
i
6/12/2017CowenInitiated CoverageOutperformHigh
i
(Data available from 10/26/2015 forward)
argenx logo
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Read More

Today's Range

Now: $250.42
$244.98
$251.35

50 Day Range

MA: $250.56
$215.51
$280.53

52 Week Range

Now: $250.42
$103.75
$284.00

Volume

132,200 shs

Average Volume

177,588 shs

Market Capitalization

$11.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1